יום חמישי, ל׳ אב תשפ״וThursday, August 13, 2026
Follow Us
Transforming "undone science" into "done science."
Hebrew University researchers unveil a chain of physiological events that may help provide new methods for disease diagnosis.
A team of neuroscientists from Bar-Ilan University is one of four winners of The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
Ten community rabbis have signed up for the 2018 RabbisCanRun program, and others expressed interest. Each participant will receive a free trip to Israel.
“We believe that this transaction will yield important benefits for NeuroDerm’s shareholders and the Parkinson’s disease patients who urgently need new therapies."
By JNi.Media
A potential future use of iPSCs is the creation of whole organs (such as heart, liver or kidney) in a suitable animal model using cells taken from the patient.
A Smartphone app may be able to help prevent Parkinson's disease patients from falling.
By Anav Silverman, Tazpit News Agency
Japan’s largest pharmaceutical company, Takeda, recently signed an agreement with Teva Pharmaceutical Industries to commercialize the Israeli company’s innovative treatment for Parkinson’s disease, rasagiline, in Japan.
August 14, 2026 
